Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Addex, Merck in schizophrenia deal

Addex (SWX:ADXN) and Merck (NYSE:MRK) partnered to develop ADX63365 to treat schizophrenia and other undisclosed indications. The positive allosteric modulator of

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE